Supplemental material

JCB





Figure S1. **RNA sequencing and proteomic analysis upon mitochondrial stress.** (A) Smear plots of RNA sequencing analysis in each condition, representing the relation of the logarithm base 2 of the fold change (logFC) relative to control and the mean of counts per million (logCPM) of each gene. (B) Volcano plots of quantitative proteomic analysis in each treatment, representing the relation of the logarithm base 10 of the p-value using a Bonferroni correction and the logarithm base 2 of fold change (log2FC). For both smear and volcano plots, genes significantly up-regulated are depicted in red and those significantly down-regulated are in blue using an FDR < 0.05. Also, the number of transcripts and proteins up- and down-regulated are shown. (C) Boxplots showing profiles of mitochondrial transcripts and proteins in RNA sequencing and quantitative proteomic analysis, respectively, showing changes in mitochondrial proteins upon treatment with the different drugs without changes in mRNA levels. (D) Venn diagram comparing the number of transcripts and proteins detected in both RNA sequencing and quantitative proteomic analysis. (E) Venn diagrams of differential expressed transcripts and proteins in RNA sequencing and proteomics in each condition using the 7,885 common transcripts and proteins detected in both analysis. Overlapping percentage of differential expressed proteins and transcripts for each condition is represented. (F) Spearman correlation analysis between the logarithm base 2 of the fold change in proteomics and RNA sequencing using the previous 7,885 transcripts/proteins. Spearman coefficient and p-value are depicted in each plot. Acti, actinonin; Dox, doxycycline; MB, MitoBloCK-6.



Figure S2. **Mitochondrial stress inhibits mitochondrial translation and decreases MRPs and OXPHOS complexes.** (A) Gene enrichment analysis using Gene Ontology (GO) categories of the 101 commonly down-regulated proteins. Enrichment is represented as negative of log10 of P value after Bonferroni correction. (B) Boxplots showing the expression of the transcripts and the relative amount of proteins of the mitochondrial ribosomal proteins (MRPs) in each condition. (C) Boxplots showing the transcript levels and relative amount of proteins of the OXPHOS components in each condition. All total complexes together (OXPHOS) or individual complexes are shown. Note that except for actinonin, in which are greatly increased, all treatments decreased the expression of all respiratory complexes. (D) Western blot analysis of OPA1 upon treatment for 6 h with each stressor. Long OPA1 isoforms (LOPA1) and short OPA1 isoforms (S-OPA1) are represented. Acti, actinonin; Dox, doxycycline; MB, MitoBloCK-6.





Ò

alpha-amino acid biosynthetic process L-serine biosynthetic process serine family amino acid biosynthetic process cellular amino acid biosynthetic process cellular amino acid metabolic process small molecule biosynthetic process carboxylic acid metabolic process oxoacid metabolic process

А

В

L-serine biosynthetic process gamma-glutamylcyclotransferase activity cellular amino acid biosynthetic process alpha-amino acid biosynthetic process L-serine metabolic process small molecule biosynthetic process carboxylic acid metabolic process oxoacid metabolic process

С

activity

Proteasome

0.4

0.0

Chi





DOT PON LOCK

NB





Figure S3. **Mitochondrial stress increases biosynthesis of amino acids.** (A) Gene enrichment analysis of the 59 genes (left; black bars) and 17 proteins (right; gray bars) commonly up-regulated in mitochondrial stress using GO categories. Enrichment is represented as negative of log10 of P value after Bonferroni correction. (B) Table representing the results obtained from GSEA of all mitochondrial stress conditions from RNA sequencing. GSEA was performed against the gene sets from CGP category (chemical and genetic perturbations). (C) Proteasome activity measured in cells treated with selected drugs for 24 h. Bars depict the relative slope in fluorogenic suc-LLVY-AMC peptide cleavage compared with control cells (n = 3 independent experiments; mean \pm SEM). (D) Heatmap and hierarchical clustering analysis of the more than 300 unique metabolites detected in our mitochondrial stress experiment. (E) Relative protein levels of glutathione cycle enzymes. Expression data were extracted from the proteomic analysis (mean values \pm SEM). *, P < 0.01; ***, P < 0.01. Acti, actinonin; Dox, doxycycline; ES, enrichment score; FDR q-val, false discovery rate adjusted p-value; FWER, family-wise error rate; MB, MitoBloCK-6; NES, normalized enrichment score; NOM p-val, nominal p-value.



Figure S4. **ATF4 mediates the mitochondrial stress response independent of the UPRer** and **UPR**^{mt}. (A) Triple Venn diagram of ATF4 and CHOP targets with common up-regulated genes, showing that 26 genes overlap with ATF4, of which 13 overlap with CHOP targets. (B) Sanger sequencing of individual deletion clone of ATF4, showing a biallelic deletion c.995delT in the exon 1. (C) Western blot analysis showing the absence of ATF4 upon addition of 50 µM actinonin (Acti) or 2.5 µg/ml tunicamycin (Tn) for 6 h. (D) Heatmap analysis of UPR^{er} transcript levels in RNA sequencing showing that this pathway was not activated under mitochondrial stress. (E) Heatmap analysis of prototypical UPR^{mt} genes in RNA sequencing showing that this pathway was not activated fashion by the different mitochondrial stress conditions. (F) Western blot analysis of mitochondrial stress protease LONP1 and UPR^{mt} proteins (HSPA9, HSPD1, and CLPP) upon transfection with empty plasmid pCAGGS (mock), wild-type ornithine transcarbamylase (OTC), and ΔOTC in HEK293T, HeLa, and Cos7 cells for 48 h. Note: ΔOTC was only detected in the insoluble fraction. (G) mRNA expression analysis of Atf4 and its target genes, *Chop* (*Ddit3*), *Atf3*, *Asns*, and *Trib3* in mouse embryonic fibroblasts (MEFs) 24 h after the addition of different mitochondrial stressors at the same concentration cells. *, P < 0.05; **, P < 0.01; ***, P < 0.001. Dox, doxycycline; MB, MitoBloCK-6.

Table S1. List of primers

| Gene | Organism | Forward (5'-3') | Reverse (5'-3') |
|------------------|----------|--------------------------|--------------------------|
| АСТВ | Human | GTCATCACCATTGGCAATGAG | CGTCATACTCCTGCTTGCTG |
| ASNS | Human | ATCACTGTCGGGATGTACCC | TGATAAAAGGCAGCCAATCC |
| ATF3 | Human | GGAGCCTGGAGCAAAATGATG | AGGGCGTCAGGTTAGCAAAA |
| ATF4 | Human | CAGCAAGGAGGATGCCTTCT | CCAACAGGGCATCCAAGTC |
| ATF5 | Human | GAGCCCCTGGCAGGTGAT | CAGAGGGAGGAGAGCTGTGAA |
| BIP | Human | CACAGTGGTGCCTACCAAGA | TGTCTTTTGTCAGGGGTCTTT |
| CHAC1 | Human | GTGGTGACGCTCCTTGAAGA | TTCAGGGCCTTGCTTACCTG |
| DDIT3 | Human | AGCCAAAATCAGAGCTGGAA | TGGATCAGTCTGGAAAAGCA |
| CLPP | Human | AAGCACACCAAACAGAGCCT | AAGATGCCAAACTCCTGGG |
| GAPDH | Human | TTGGTATCGTGGAAGGACTC | ACAGTCTTCTGGGTGGCAGT |
| HSPA9 | Human | TGGTGAGCGACTTGTTGGAAT | ATTGGAGGCACGGACAATTTT |
| HSPD1 | Human | GGGTAACCGAAGCATTTCTGC | CTGCACTCTGTCCCTCACTC |
| HSPE1 | Human | AGTAGTCGCTGTTGGATCGG | TGCCTCCATATTCTGGGAGA |
| LONP1 | Human | CCCGCGCTTTATCAAGATT | AGAAAGACGCCGACATAAGG |
| PCK2 | Human | CATCCGAAAGCTCCCCAAGT | GCTCTCTACTCGTGCCACAT |
| PHGDH | Human | GCAAAGAGGAGCTGATAGCG | TTCTCAGCTGCGTTGATGAC |
| PSPH | Human | GAGGACGCGGTGTCAGAAAT | GGTTGCTCTGCTATGAGTCTCT |
| FH | Human | GGAGGTGTGACAGAACGCAT | CATCTGCTGCCTTCATTATTGC |
| HRI | Human | GTTCGTCAGGATCCTTGTGAGG | ACGTGAAGTTTGTGCTTCCAA |
| PKR | Human | TCGTTGCTTATGAATGGTCTCAG | AGGTCAAATCTGGGTGCCAA |
| PERK | Human | GCACTCAGATGGAGAGAGTCA | AACCATCACGTACTCACAAGGA |
| GCN2 | Human | GTGAAATTGAAATTCTGGCTGTGG | ATGCCTGTTCATCAGCATCC |
| tRNA-Leu (mtDNA) | Human | GATGGCAGAGCCCGGTAATCGC | TAAGCATTAGGAATGCCATTGCG |
| POLG (nDNA) | Human | AGCGACGGGCAGCGGCGGCGGCA | CCCTCCGAGGATAGCACTTGCGGC |
| Actb | Mouse | TGTTACCAACTGGGACGACA | GGGGTGTTGAAGGTCTCAAA |
| Asns | Mouse | GAGAAACTCTTCCCAGGCTTTG | CAAGCGTTTCTTGATAGCGTTGT |
| Atf3 | Mouse | ATGATGCTTCAACACCCAGGC | TTAGCTCTGCAATGTTCCTTC |
| Atf4 | Mouse | GCCGGTTTAAGTTGTGTGCT | CTGGATTCGAGGAATGTGCT |
| Chop | Mouse | CGGAACCTGAGGAGAGAGTG | CGTTTCCTGGGGATGAGATA |
| Gapdh | Mouse | TGTGTCCGTCGTGGATCTGA | CCTGCTTCACCACCTTCTTGAT |
| Trib3 | Mouse | TGTCTTCAGCAACTGTGAGAGGA | CAGTCATCACGCAGGCATC |

Table S2. List of shRNAs

| Gene | Clone |
|-------|----------------|
| HRI | TRCN0000194754 |
| HRI | TRCN0000195265 |
| PKR | TRCN0000197012 |
| PKR | TRCN0000196400 |
| PERK | TRCN0000197197 |
| PERK | TRCN0000262380 |
| GCN2 | TRCN0000300851 |
| GCN2 | TRCN0000300850 |
| LONP1 | TRCN0000291803 |
| LONP1 | TRCN0000310154 |
| FH | TRCN0000052464 |
| FH | TRCN0000052465 |

Provided online are six Excel tables. Table S3 shows RNA sequencing results of mitochondrial stress. Table S4 shows TMT-based quantitative proteomic analysis of mitochondrial stress. Table S5 shows common differential expressed genes and proteins in mitochondrial stress. Table S6 shows gene enrichment analysis of each stressor in RNA sequencing analysis. Table S7 shows enrichment analysis of each stressor in TMT-quantitative proteomic analysis. Table S8 shows nontargeted metabolomics raw data of mitochondrial stress.